Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study

Table 4 Rituximab first discontinuation hazards ratio by indication and other factors of interest, multivariate Cox regression analysis

Rituximab first discontinuation	Adjusted Hazard ratio^a	95% CI	P
Rituximab indication			p = 0.004
RA	Reference
CTD	0.87	0.57, 1.33
Vasculitis	2.45	1.13, 5.30
Other inflammatory conditions	2.42	1.25, 4.68
Age at first RTX	1.00	0.99, 1.01	p = 0.96
Gender: male	0.98	0.66, 1.45	p = 0.91
Charlson comorbidity index	1.10	0.98, 1.24	p = 0.11
RF positivity	0.61	0.42, 0.90	p = 0.01
Previous treatment with csDMARD (any)	1.26	0.63, 2.53	p = 0.51
Concomitant treatment with csDMARD (any)	0.74	0.52, 1.06	p = 0.10

RA Rheumatoid arthritis, CTD Connective tissue disease, RTX Rituximab, RF Rheumatoid factor
^aFactors are adjusted for each other

ISSN: 1478-6362